Dr. Peter Bongiorno, Naturopathic Doctor
- PRP Therapy
- Arthritis Treatment
- Migraine Treatment
- Hormone Replacement Therapy (HRT)
New York, NY
Migraine Treatment clinics in New York
New York has 12 providers offering migraine care, spanning conventional neurology and regenerative or integrative options. The conventional stack includes triptans, CGRP inhibitors like Aimovig, Emgality, Ajovy, and Nurtec ODT, and onabotulinumtoxinA (Botox) for chronic migraine, which is FDA-approved for that indication. On the regenerative and device side, eNeura's sTMS mini is FDA-cleared for acute and preventive treatment of migraine with aura. Occipital and sphenopalatine ganglion nerve blocks are commonly used off-label in New York clinics, typical cost 150 to 400 dollars per injection. PRP scalp injections and neurofeedback are offered by some integrative practices, though evidence for PRP in migraine is Insufficient. New York insurers generally cover CGRP inhibitors and Botox for chronic migraine (15 or more headache days per month) when step therapy is documented. A reputable New York migraine clinic will start with a neurology evaluation, headache diary, and imaging when red flags are present before escalating to device or procedural options.
Pain Management NYC
- PRP Therapy
- Arthritis Treatment
- Migraine Treatment
- Hormone Replacement Therapy (HRT)
- Stem Cell Therapy
Hyperbaric Medical Solutions
- PRP Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
- Ketamine Therapy
LEDA Medical
- IV Therapy
- Arthritis Treatment
- Lyme Disease Treatment
- Migraine Treatment
- NAD IV Therapy
New York Headache Center
- Biofeedback Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Migraine Treatment
Neurotherapeutix Medical Services
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Migraine Treatment
Hudson Medical
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Migraine Treatment
LEAA Health - Medical House Calls
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
- Migraine Treatment
Halcyon Life
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
- Multiple Sclerosis (MS) Treatment
- Lyme Disease Treatment
- Migraine Treatment
Regulatory context
A note on New York's migraine treatment rules.
Repetitive transcranial magnetic stimulation (rTMS) is regulated as a Class II prescription device. The first 510(k) clearance went to NeuroStar in 2008 for treatment-resistant major depressive disorder. Subsequent clearances expanded the on-label scope to obsessive-compulsive disorder (BrainsWay deep TMS, 2018), smoking cessation (BrainsWay, 2020), anxious depression as an adjunct indication (2021), and migraine via single-pulse TMS devices such as eNeura SpringTMS and SAVI Dual. Biofeedback instruments are cleared under 21 CFR 882.1425 as Class II devices for relaxation training and stress reduction. EEG-based neurofeedback systems hold 510(k) clearances in the same category. Cranial electrotherapy stimulation, tDCS wellness devices, and many vagus nerve stimulation accessories sold direct to consumers are not cleared as medical devices, and clinical claims beyond cleared indications are off-label.
-
New York Education Law Article 131 (Medicine)
Defines the practice of medicine and supervision framework for delegated procedures including TMS technician work. -
New York Education Law Article 153 (Psychology)
Governs licensed psychologists who deliver biofeedback and neurofeedback within scope. -
New York General Business Law Sections 349 and 350
Supports attorney general action against deceptive medical device advertising.
The New York State Office of Professional Medical Conduct investigates TMS clinics for supervision lapses, corporate practice violations, and off-label marketing. New York enforces a strong corporate practice of medicine doctrine and requires Professional Service Corporation or similar structures for clinical ownership. The New York attorney general pursues General Business Law Sections 349 and 350 actions against deceptive medical device advertising, including neurofeedback cure claims. Commercial insurers and New York Medicaid typically require documented treatment-resistant depression before covering TMS for major depressive disorder.